Skip to main content
OpenTrials
Completed

NCT Number: NCT00977821

Embryo Developmental Capacity After Egg Banking in an Ovum Donation Program

For an efficient "egg banking" system, an equally efficient cryopreservation strategy that ensures the viability of the oocytes is required. Very recently, improved and new methods are yielding satisfactory results. In particular, vitrification is providing excellent results for both survival and clinical outcomes. However, to evaluate the over all out come there are other parameters to be considered. In this sense, capacity development of embryos generated after oocyte vitrification is a major factor when assessing the viability of vitrified oocytes. Accordingly, the evaluation of the capacity of vitrified oocytes to reach the blastocyst stage will be highly valuable to fully assess the effectiveness of the "egg banking" and its contribution to ovum donation programs.

The aim of this study is to evaluate the developmental capacity of vitrified oocytes by their ability to reach the blastocyst stage. The study includes oocyte donation cycles conducted with vitrified versus fresh oocytes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

IVI Valencia

Valencia, 46015, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-35 year old
  • Normal response (8-15 follicles) to long protocol of ovarian stimulation with hCG
  • Donors with normal menstrual cycles (21-35 day duration)
  • Donors with BMI between 18-25 Kg/m2

Exclusion criteria

  • Donors with two or more previous miscarriages
  • Polycystic ovary syndrome
  • Donors with antecedents of poor embrionary quality not attributed to masculine factor
  • Donors with drop of estradiol of more than 10% or estradiol plateau.
  • Donors with a high response>20 oocytes and or levels above 3000pg/ml of estradiol the day of the administration of chorionic gonadotrophin (hCG)

Treatment and study plan

IVF

Other

Oocyte Vitrification

Other

Primary outcomes

  1. Mean outcome measures will be survival, fertilization and blastocyst rates and clinical outcome.

    Time frame: 10 months

Sponsors and collaborators

Lead sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Other

Registry information

Important dates

Study start
2009
Primary completion
2014
Study completion
2014
First posted
Sep 16, 2009
Registry last updated
Apr 22, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.